The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers

Drug and Alcohol Dependence

Volumn 139, Issue , 2014, Pages 9-17

  Havens, Jennifer R ^a   Leukefeld, Carl G ^a   DeVeaugh Geiss, Angela M ^b   Coplan, Paul ^b   Chilcoat, Howard D ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

Abuse deterrent formulation; ER oxycodone; Extended release oxycodone; Prescription opioid abuse; Tamper resistant formulation

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; CANNABIS; COCAINE; DIAMORPHINE; HYDROCODONE; METHADONE; OXYCODONE; DELAYED RELEASE FORMULATION;

ADULT; ALCOHOL ABUSE; ARTICLE; CANNABIS ADDICTION; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL AREA; STRUCTURED INTERVIEW; UNITED STATES; DELAYED RELEASE FORMULATION; INTERVIEW; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; STATISTICS AND NUMERICAL DATA;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; OPIOID-RELATED DISORDERS; OXYCODONE; PRESCRIPTION DRUG MISUSE; PREVALENCE;

EID: 84899977870     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.02.018     Document Type: Article

References (40)

1. Barsky A.J. Forgetting, fabricating, and telescoping: the instability of the medical history. Arch. Intern. Med. 2002, 162:981-984.
2. Buer L.-M., Havens J.R., Leukefeld C.G. Changing drug use patterns in rural Appalachia: a qualitative analysis. Subst. Use Misuse 2014, (in press). 10.3109/10826084.2013.866963.
3. Butler S.F., Black R.A., Serrano J.M., Wood M.E., Budman S.H. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J. Opioid Manag. 2010, 6:239-241. 246-252.
4. Butler S.F., Cassidy T.A., Chilcoat H., Black R.A., Landau C., Budman S.H., Coplan P.M. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J. Pain 2013, 14:351-358.
5. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. N. Engl. J. Med. 2012, 367:187-189.
6. Cicero T.J., Surratt H., Inciardi J.A., Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol. Drug Saf. 2007, 16:827-840.
7. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006, 81:103-107.
8. Cone E.J., Giordano J., Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013, 131:100-105.
9. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51:253-263. (discussion 267-268).
10. Degenhardt L., Day C., Dietze P., Pointer S., Conroy E., Collins L., Hall W. Effects of a sustained heroin shortage in three Australian States. Addiction 2005, 100:908-920.
11. Embeda [package insert], 2012. King Pharmaceuticals Inc., Bristol, TN.
12. FDA Advisory Committee Transcript Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement October 21, 2010, http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm193298.htm (accessed 2.07.13).
13. FDA Guidance for Industry Abuse Deterrent Opioids - Evaluation and Labeling Draft Guidance 2013, www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory (accessed 2.07.13).
14. Fountain J., Strang J., Gossop M., Farrell M., Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000, 95:393-406.
15. Gfroerer J., Hughes A., Chromy J., Heller D., Packer L. Estimating trends in substance use based on reports of prior use in a cross-sectional survey. Eighth Conference on Health Survey Research Methods: Conference Proceedings 2004, 29-34. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD, Available as a PDF at http://www.cdc.gov/nchs/data/misc/proceedings_hsrm2004.pdf. S.B. Cohen, J.M. Lepkowski (Eds.).
16. Havens J.R., Lofwall M.R., Frost S.D., Oser C.B., Leukefeld C.G., Crosby R.A. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am. J. Public Health 2013, 103:e44-e52.
17. Havens J.R., Walker R., Leukefeld C.G. Prescription opioid use in the rural Appalachia: a community-based study. J. Opioid Manag. 2008, 4:63-71.
18. Havens J.R., Walker R., Leukefeld C.G. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend. 2007, 87:98-102.
19. Havens J.R., Oser C.B., Leukefeld C.G., Webster J.M., Martin S.S., O'Connell D.J., Surratt H.L., Inciardi J.A. Differences in prevalence of prescription opiate misuse among rural and urban probationers. Am. J. Drug Alcohol Abuse 2007, 33:309-317.
20. Hays L.R. A profile of OxyContin addiction. J. Addict. Dis. 2004, 23:1-9.
21. Katz N., Dart R.C., Bailey E., Trudeau J., Osgood E., Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am. J. Drug Alcohol Abuse 2011, 37:205.
22. Kokkevi A., Richardson C., Palermou B., Leventakou V. Reliability of drug dependents' self-reports. Drug Alcohol Depend. 1997, 45:55-61.
23. Kumar M.S., Agrawal A. Scale-up of opioid substitution therapy in India: opportunities and challenges. Int. J. Drug Policy 2012, 23:169-170.
24. Leukefeld C.G., Logan T.K., Farabee D., Clayton R. Drug use and AIDS: estimating injection prevalence in a rural state. Subst. Use Misuse 2002, 37:767-782.
25. Liang K.-Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
26. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The fifth edition of the addiction severity index. J. Subst. Abuse Treat. 1992, 9:199-213.
27. Office of National Drug Control Policy 2012 National Drug Control Strategy 2012, http://www.whitehouse.gov/ondcp/2012-national-drug-control-strategy (accessed 18.10.12).
28. Office of National Drug Control Policy Prescription Drug Abuse 2012, http://www.whitehouse.gov/ondcp/prescription-drug-abuse (accessed 18.10.12).
29. Opana [package insert], 2011. Novartis Consumer Health, Lincoln, NE.
30. OxyContin [package insert], 2013. Purdue Pharma L.P., Stamford, CT.
31. ® tablets in healthy adults. Clin. Drug Investig. 2013, 33:441-449.
32. Sellers E.M., Perrino P.J., Colucci S.V., Harris S.C. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J. Psychopharmacol. 2013, (Epub ahead of print).
33. Severtson S.G., Bartelson B.B., Davis J.M., Munoz A., Schneider M.F., Chilcoat H., Coplan P.M., Surratt H., Dart R.C. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release Oxycodone in 2010. J. Pain 2013, (Epub ahead of print).
34. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
35. Tang Y.L., Zhao D., Zhao C., Cubells J.F. Opiate addiction in China: current situation and treatments. Addiction 2006, 101:657-665.
36. Young A.M., Havens J.R. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction 2012, 107:587-596.
37. Young A.M., Havens J.R., Leukefeld C.G. A comparison of rural and urban nonmedical prescription opioid users' lifetime and recent drug use. Am. J. Drug Alcohol Abuse 2012, 38:220-227.
38. Young A.M., Havens J.R., Leukefeld C.G. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct. J. 2010, 7:24. 10.1186/1477-7517-7-24.
39. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003, 69:215-232.
40. Zeger S.L., Liang K.-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometries 1986, 42:121-130.